Supreme Court order gives religious organizations new chance to challenge New York abortion rule
WASHINGTON (AP) — The Supreme Court on Monday ordered a New York court to take a new look at whether some religious organizations should be excluded from a state regulation requiring health insurance plans to cover abortions.
The justices acted after the court unanimously ruled earlier in June that Wisconsin discriminated against a Catholic charity by forcing it to pay state unemployment taxes.
The New York case poses a similar issue because the state exempts religious employers if their purpose is to spread religious values and they primarily employ and serve people of their faith. But religious groups that serve and employ people regardless of their beliefs don't qualify for the exemption.
The Roman Catholic Diocese of Albany and other church groups challenged the rule.
It's the second time the nation's highest court has sent the case back to New York courts. Last year, the New York Court of Appeals upheld the regulation after taking into account the Supreme Court's unanimous ruling in 2021 in favor of a Catholic foster care agency in Philadelphia that refused to work with same-sex couples because of its religious opposition to same-sex marriage.
___
Follow the AP's coverage of the U.S. Supreme Court at https://apnews.com/hub/us-supreme-court.
The Associated Press
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
an hour ago
- Boston Globe
Dismissed members of CDC vaccine committee call RFK Jr.'s actions ‘destabilizing'
'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Association. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria. Advertisement In addition to Wharton's removal, CDC immunization staff have been cut and agency experts who gather or present data to committee members have resigned. One, Dr. Lakshmi Panagiotakopoulos, resigned after 12 years at CDC, disclosing her decision early this month in a note to members of a COVID-19 vaccines workgroup. Her decision came after Kennedy decided — without consulting the vaccine advisers — to pull back COVID-19 vaccination recommendations for healthy children and pregnant women. Advertisement 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in a message viewed by the AP. Those CDC personnel losses will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about which vaccines to recommend to the public, the former committee members said. 'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote. A spokeswoman for the U.S. Department of Health and Human Services did not respond to the JAMA commentary, but instead pointed to Kennedy's previous comments on the committee. Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak.
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Dismissed members of CDC vaccine committee call Kennedy's actions 'destabilizing'
NEW YORK (AP) — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying 'destabilizing decisions" made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread. Kennedy last week announced he would 'retire' the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings. Two days later, he named eight new people to the influential panel. The list included a scientist who criticized COVID-19 vaccines, a leading critic of pandemic-era lockdowns and someone who worked with a group widely considered to be a leading source of vaccine misinformation. 'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Association. The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria. The removal of Wharton and CDC immunization staff cuts will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about what vaccines to recommend and not recommend to the public, the experts said. 'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote. Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak.
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Second patient death reported with gene therapy for muscular dystrophy
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males. Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading. Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership. 'Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,' said Leerink Partners analyst Joseph Schwartz, in a Sunday research note. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
